Objectives
The Cell Unit specializes in performing cell-based tests and analyses for R&D, particularly in the fields of cancer and infectious diseases.
Equipped with state-of-the-art technology, the Cell Unit provides accredited diagnostic tests for clinical trials, providing adding value to SMEs and researchers.
Areas of impact and applications in the field
Recent advances in bacterial and mammalian cell engineering include the development of cells that function in biological samples or within the body as minimally invasive diagnostics or theranostics for the real-time regulation of complex pathological conditions. Ex-vivo and in-vivo cell-based biosensors and therapeutics have been developed to target various diseases including cancer.
A significant milestone in the field of theranostic cell engineering was the 2017 FDA approval of tisagenlecleucel, the first gene therapy to be approved in the USA. Considering the above, this facility will work on preclinical applications of mammalian sensing and drug delivery platforms and underlying biological designs that could lead to innovative cell diagnostics and therapeutics.
There is a growing need for novel, specific, sensitive, and compelling diagnostic and treatment procedures in infectious diseases. Synthetic systems and devices are evolving into robust tools for treating human infections. The advancement of synthetic biology provides efficient, accurate, and cost-effective platforms for detecting, preventing, and treating infectious diseases .
Areas of impact and applications in the field
Regarding cancer research, synthetic biology seeks to re-design biological systems to perform novel functions in a predictable way. Recent advances in bacterial and mammalian cell engineering include the development of cells that function in biological samples or within the body as minimally invasive diagnostics or theranostics for the real-time regulation of complex pathological conditions. Ex-vivo and in-vivo cell-based biosensors and therapeutics have been developed to target a wide range of diseases including cancer.
A major milestone in the field of theranostic cell engineering was the 2017 FDA approval of tisagenlecleucel, the first gene therapy to be approved in the USA. Considering the above, this facility will work on preclinical applications of mammalian sensing and drug delivery platforms as well as underlying biological designs that could lead to new classes of cell diagnostics and therapeutics.
In the context of infectious diseases, there is a growing need for novel, specific, sensitive, and effective diagnostic and treatment procedures. Synthetic systems and devices are evolving into strong tools for treating human infections. The advancement of synthetic biology provides platforms for detecting and preventing infectious diseases that are efficient, accurate, and cost-effective.
Services
List of Equipments
Staff
